Course of ulcerative colitis: Analysis of changes in disease activity over years

Langholz, Ebbe; Munkholm, Pia; Davidsen, Michael; Binder, Vibeke

doi:10.1016/0016-5085(94)90054-x

Cited by 648 publications

(376 citation statements)

References 12 publications

Supporting

Mentioning

321

Contrasting

Unclassified

Order By: Relevance

Section: Introductionmentioning

confidence: 99%

“…Its clinical course is characterized by exacerbations and remissions (5,20,27) . Although ex-cess mortality associated with URCC is not observed, a severe attack of the disease is potentially fatal (13,20,27) . The cumulative risk of colectomy after 10 years of diagnosis is around 10%, but reaches 20% in patients with extensive disease (27) , who also have 15 times the risk of colorectal neoplasia (9) .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Decision Tree Construction and Cost-Effectiveness Analysis of Treatment of Ulcerative Colitis With Pentasa®mesalazine 2 G Sachet

Nishikawa

Paladini

Delfini

et al. 2013

Arq. Gastroenterol.

View full text Add to dashboard Cite

-Context -Unspecified Ulcerative Rectocolitis is a chronic disease that affects between 0.5 and 24.5/10 5 inhabitants in the world. National and international clinical guidelines recommend the use of aminosalicylates (including mesalazine) as first-line therapy for induction of remission of unspecified ulcerative rectocolitis, and recommend the maintenance of these agents after remission is achieved. However, multiple daily doses required for the maintenance of disease remission compromise compliance with treatment, which is very low (between 45% and 65%). Use of mesalazina in granules (2 g sachet) once daily -Pentasa ® sachets 2 g -can enhance treatment adherence, reflecting in an improvement in patients' outcomes. Objective -To evaluate the evidence on the use of mesalazine for the maintenance of remission in patients with unspecified ulcerative rectocolitis and its effectiveness when taken once versus more than once a day. From an economic standpoint, to analyze the impact of the adoption of this dosage in Brazil's public health system, considering patients' adherence to treatment. Methods -A decision tree was developed based on the Clinical Protocol and Therapeutic Guidelines for Ulcerative Colitis, published by the Ministry of Health in the lobby SAS/MS n° 861 of November 4 th, 2002 and on the algorithms published by the Associação Brasileira de Colite Ulcerativa e Doença de Crohn, aiming to get the cost-effectiveness of mesalazine once daily in granules compared with mesalazine twice daily in tablets. ResultsThe use of mesalazine increases the chances of remission induction and maintenance when compared to placebo, and higher doses are associated with greater chance of success without increasing the risk of adverse events. Conclusion -The use of a single daily dose in the maintenance of remission is effective and related to higher patient compliance when compared to the multiple daily dose regimens, with lower costs.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Decision Tree Construction and Cost-Effectiveness Analysis of Treatment of Ulcerative Colitis With Pentasa®mesalazine 2 G Sachet

Nishikawa

Paladini

Delfini

et al. 2013

Arq. Gastroenterol.

View full text Add to dashboard Cite

show abstract

“…Ulcerative colitis (UC) is a chronic inflammatory disease of the intestines with a continuously active or relapsing, remitting course in most patients (1). The mainstay of the treatment is corticosteroids, especially in severe cases, but they can cause side effects in up to 50% of the cases (2).…”

Section: Introductionmentioning

confidence: 99%

How long should we treat patients with azathioprine/ 6-mercaptopurine before deciding that it is refractory to immunomodulatory treatment?

Kabaçam

Törüner²

2012

Turk J Gastroenterol

View full text Add to dashboard Cite

show abstract

“…The disease presents itself typically by remission and relapses, so that in the first year after the diagnosis, 40%-50% of the cases are clinically in remission, whereas only 25% remain in remission 3-7 years later (1). Moreover, 18% of the cases remain continuously active, and 57% of them have a course with intermittent relapses.…”

Section: Introductionmentioning

confidence: 99%

Can azathioprine/6-mercaptopurine treatment be withdrawn in patients with response in ulcerative colitis: What is the most appropriate time for this?

Kabaçam

Törüner²

2012

Turk J Gastroenterol

View full text Add to dashboard Cite

show abstract

Course of ulcerative colitis: Analysis of changes in disease activity over years

Cited by 648 publications

References 12 publications

Decision Tree Construction and Cost-Effectiveness Analysis of Treatment of Ulcerative Colitis With Pentasa®mesalazine 2 G Sachet

Decision Tree Construction and Cost-Effectiveness Analysis of Treatment of Ulcerative Colitis With Pentasa®mesalazine 2 G Sachet

How long should we treat patients with azathioprine/ 6-mercaptopurine before deciding that it is refractory to immunomodulatory treatment?

Can azathioprine/6-mercaptopurine treatment be withdrawn in patients with response in ulcerative colitis: What is the most appropriate time for this?

Contact Info

Product

Resources

About